Journal of Life Science and Biomedicine

ISSN: 2251-9939; http://jlsb.science-line.com

How to Cite this Article

APA:

IBADOV, R. A., KHAMRAEVA, G. S., & IBRAGIMOV, S. K. (2021). Anticoagulant therapy in patients with atypical COVID-19 pneumonia. Journal of Life Science and Biomedicine, 11(3), 30–35. doi:10.51145/jlsb.2021.5

Harvard:

IBADOV, R.A., KHAMRAEVA, G.S. & IBRAGIMOV, S.K., 2021. Anticoagulant therapy in patients with atypical COVID-19 pneumonia. Journal of Life Science and Biomedicine, 11(3), pp.30–35. Available at: http://dx.doi.org/10.51145/jlsb.2021.5.

IEEE:

[1]R. A. IBADOV, G. S. KHAMRAEVA, and S. K. IBRAGIMOV, “Anticoagulant therapy in patients with atypical COVID-19 pneumonia,” Journal of Life Science and Biomedicine, vol. 11, no. 3, pp. 30–35, May 2021.

MLA:

IBADOV, Ravshan Aliyevich, Gulchekhra Shakhobovna KHAMRAEVA, and Sardor Khamdamovich IBRAGIMOV. “Anticoagulant Therapy in Patients with Atypical COVID-19 Pneumonia.” Journal of Life Science and Biomedicine 11.3 (2021): 30–35. Crossref. Web.

Vancouver:

1. IBADOV RA, KHAMRAEVA GS, IBRAGIMOV SK. Anticoagulant therapy in patients with atypical COVID-19 pneumonia. Journal of Life Science and Biomedicine [Internet]. Journal of Life Science and Biomedicine; 2021 May 25;11(3):30–5. Available from: http://dx.doi.org/10.51145/jlsb.2021.5

Chicago: